

Dinutuximab

PRELIMINARY SCORE


CURATIVE


DFS

NON-CURATIVE


ADJUSTMENTS


Quality of life







Serious and disabling adverse effects





Other adjustments





Dinutuximab

FINAL SCORE

CURATIVE

A

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Central Nervous System Malignancies

Therapeutic Indication: <32 years old with high-risk neuroblastoma after remission and stem cell transplatation

Experimental Arm: Dinutuximab + Cis retinoic acid+GMCSF+IL2

Control Arm: Cis retinoic acid

